bluebird bio
BLUE
BLUE was delisted on the 30th of May, 2025.
251 hedge funds and large institutions have $6.06B invested in bluebird bio in 2018 Q4 according to their latest regulatory filings, with 37 funds opening new positions, 98 increasing their positions, 76 reducing their positions, and 73 closing their positions.
92% more call options, than puts
Call options by funds: $169M | Put options by funds: $88.3M
29% more repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 76
5.62% more ownership
Funds ownership: 107.23% → 112.85% (+5.6%)
13% less funds holding
Funds holding: 288 → 251 (-37)
28% less capital invested
Capital invested by funds: $8.48B → $6.06B (-$2.41B)
49% less first-time investments, than exits
New positions opened: 37 | Existing positions closed: 73
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$358M |
| 2 |
Capital International Investors
Los Angeles,
California
|
+$212M |
| 3 |
Fiera Capital (Canada)
Montreal,
Quebec, Canada
|
+$39.4M |
| 4 |
Capital World Investors
Los Angeles,
California
|
+$34M |
| 5 |
Two Sigma Investments
New York
|
+$30.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$164M |
| 2 |
Bank of New York Mellon
New York
|
-$42.2M |
| 3 |
RG
Redmile Group
San Francisco,
California
|
-$36.8M |
| 4 |
AllianceBernstein
Nashville,
Tennessee
|
-$33.3M |
| 5 |
MCM
Masters Capital Management
Atlanta,
Georgia
|
-$30.7M |
BLUE Hedge Fund Activity: Q4 2018 in Review
251 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q4 2018, worth a combined $6.06B — down 28% from $8.48B a quarter earlier.
Sellers outnumbered buyers: 73 funds closed out of BLUE and 37 opened new positions — a net loss of 36 holders — while 76 trimmed existing stakes and 98 added.
The largest buyer was Wellington Management Group, adding an estimated $358M. The largest seller was T. Rowe Price Associates, cutting an estimated $164M.
- 251 institutional investors held bluebird bio (BLUE) as of Q4 2018, down from 288 in Q3 2018.
- Funds reported $6.06B of bluebird bio stock for Q4 2018, down 28% quarter-over-quarter.
- 37 funds opened new bluebird bio positions in Q4 2018 and 73 closed out, a net change of -36 holders.
- The largest bluebird bio buyer in Q4 2018 was Wellington Management Group, an estimated $358M added.
- The largest bluebird bio seller in Q4 2018 was T. Rowe Price Associates, an estimated $164M sold.
Based on aggregated 13F filings for Q4 2018.